Uncategorized

Children and COVID19: State Level Data Report | Placental Tissue Destruction and Insufficiency from COVID-19 Causes Stillbirth and Neonatal Death from Hypoxic-Ischemic Injury: A Study of 68 Cases with SARS-CoV-2 Placentitis from 12 Countries | Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report | Azithromycin in patients with COVID-19: a systematic review and meta-analysis | Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022

Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods | Children and COVID19: State Level Data Report
| Safety, tolerability and viral kinetics during SARS-CoV-2 viral challenge
| Long-term cardiovascular outcomes of COVID-19 | FDA to discuss request authorization for the Pfizer COVID-19 Vaccine for use in children 6 months-4 years | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron | Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

Children and COVID19: State Level Data Report | Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant | Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods | Associations between adverse childhood experiences, attitudes towards COVID-19 restrictions and vaccine hesitancy: a cross-sectional study | U.S. FDA approves the Moderna COVID-19 Vaccine (Spikevax) for the prevention of COVID-19 in individuals 18 years of age and older | Novavax Submitted a Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022 | Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C | Viral Interference between Respiratory Viruses | Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–

COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021 | SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland | Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021 | Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron | Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England

Children and COVID19: State Level Data Report | Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron – Retrospective Cohort Study | Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron | Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021 | Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts

COVID-19: State-Level Data Report | Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 – Six Hospitals, United States, July-August 2021 | Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared with Previous Waves | CDC Advisory Committee on Immunization Practices panel endorsed Pfizer and BioNTech’s Covid booster shots for 12 to 15-years olds | Risk Factors for Severe COVID-19 Outcomes Among Persons Aged >18 years who completed a primary COVID19 vaccination series

CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population | Children and COVID-19: State-Level Data Report | Texas Children’s Hospital and Baylor College of Medicine COVID-19 Vaccine Technology Secures Emergency Use Authorization in India

Children and COVID-19: State Data Report | Duration of SARS-CoV-2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study | Quarantine and Isolation | Frequently Asked Questions on the Emergency Use Authorization for Paxlovid for Treatment of COVID-19